Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”).
- Kaplan Fox & Kilsheimer LLPKaplan Fox Advises Capricor Therapeutics, Inc. (CAPR) Investors of a Securities Class Action Deadline on September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also...
- BostonGeneBostonGene to Showcase Novel Genomic Classifier and Immunotherapy Selection Framework at SOHO 2026WALTHAM, Mass., August 31, 2026--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that two abstracts have been accepted for poster presentation at Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9 - 12 in Houston, Texas. The 14th Annual Meeting will bring together thousands of global experts to showcase practice-changing breakthroughs and practical clinical applications in blood cancer treatment.
- FDA Clearance Advances Prescription ADHD TherapeuticsKey opportunities include prescription digital therapeutics, behavioral management, cognitive training and productivity apps for children and adults, distributed through consumers, caregivers, schools, employers and healthcare providers.
- Dr. Tobias Janowitz joins Feinstein Institutes as new Institute of Cancer Research directorMANHASSET, N.Y., August 31, 2026--At the Feinstein Institutes for Medical Research, clinicians and scientists produce knowledge to cure disease, conducting clinical trials and basic and translational science to improve cancer treatment. To help propel the Feinstein Institutes’ cancer research, Tobias Janowitz, MD, PhD, has been appointed director of its Institute of Cancer Research. In addition, he will take on the roles of Robert and Janet Perro Professor in Cancer Research and director of Tran
- Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)Company announcement No. 44 / 2026
- BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology EcosystemOTTAWA, Ontario, August 31, 2026--BIOTECanada, the national industry association representing Canada’s biotechnology sector, is pleased to announce the winners of the 2026 Gold Leaf Awards, recognizing outstanding leadership, innovation and impact across Canadian biotech.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (FULC) of a Securities Law InvestigationKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
- Oligomerix Appoints Biopharmaceutical Industry Veteran Cara Cassino, M.D. as Interim President and Chief Executive OfficerBRONX, N.Y., August 31, 2026--Cassino appointed Interim President and CEO of Oligomerix
- Coherus Oncology, Inc.Coherus to Participate in Upcoming Investor ConferencesCoherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
- TransCode Therapeutics, Inc.TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisPublished study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and...
- Adia Med Inc.From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media TeamAdia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing.From Full Sail...